01:43 AM EDT, 08/05/2026 (MT Newswires) -- Basilea Pharmaceutica (BSLN.SW) received an additional $5.4 million in funding from the Biomedical Advanced Research and Development Authority, or BARDA, for the ongoing development of the oral antibiotic ceftibuten-ledaborbactam etzadroxil. The drug candidate, which is a beta-lactam/beta-lactamase inhibitor combination, is being developed to treat complicated urinary tract infections, including pyelonephritis, according to a Wednesday release. BARDA, which is part of the US Department of Health and Human Services' Administration for Strategic Preparedness and Response, has so far funded $30.8 million to the commercial-stage biopharmaceutical company. The contract has the potential to provide up to $172 million in non-dilutive funding.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.